Zhouping Wang

Dr. Zhouping Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ZWZhouping Wang
Zhouping Wang
FCFeiyan Chen
Feiyan Chen
YWYanfei Wang
Yanfei Wang
WLWei Li
Wei Li
XXXiaofei Xie
Xiaofei Xie
PHPing Huang
Ping Huang
There have been no robust data from clinical trials to guide the clinician in the choice of therapeutic agents for the child with intravenous immunoglobulin (IVIG) resistance. The treatment regimen for IVIG-resistant patients varies between institutions, and the best option has not yet been established. Therefore, in this trial, a total of 955 patients with Kawasaki disease (KD) were selected and were initially treated with IVIG (2 g/kg), of whom 80 (8.38%) assessed as IVIG resistant were randomly divided into two groups: Group A received the second IVIG treatment ( ), and Group B received methylprednisolone pulse therapy (MPT, ). The whole fever time, duration of fever after retreatment, hospital days, medical costs, readmission rate, and laboratory examination difference (△) were calculated. Coronary artery lesion (CAL) outcomes were followed up over two years. Patients in the MPT group had shorter fever after retreatment and lower medical costs; more rapid declines in C-reactive protein (CRP), neutrophils (N%), and platelet (PLT) levels; and more rapid rise in sodium. However, they also probably had a higher incidence of treatment failure and CALs than the additional IVIG treatment group in the long-term follow-up. Caution is still required in the use of MPT to treat IVIG-resistant KD.

18 June 2021 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
WLWei Li
Wei Li
XHXiufang He
Xiufang He
LZLi Zhang
Li Zhang
ZWZhouping Wang
Zhouping Wang
YWYanfei Wang
Yanfei Wang
PHPing Huang
Ping Huang
Background. Although intravenous immunoglobulin (IVIG) is expected to prevent coronary artery abnormalities of Kawasaki disease (KD) in the acute phase, the timing and effectiveness of IVIG remain to be determined. The association of timing of IVIG administration in KD patients with coronary artery abnormalities is evaluated in this cohort study. Methods. We systematically studied KD patients from two participating institutions between 2015 and 2017. To reveal the effectiveness of IVIG treatment, these patients were classified into four groups regarding the time of IVIG treatment. Primary outcome was coronary artery abnormalities by echo at diagnosis and 12 months follow-up; secondary outcomes included inflammatory markers. Results. A total of 1281 patients were included in this study. The best time of IVIG treatment cut-off values in 12 months follow-up for predicting coronary artery abnormalities was days 7.5 of illness onset. According to the best time of IVIG treatment cut-off values, all patients were classified into 4 groups. Group 1 was defined as earlier IVIG treatment administration on days ≤4 of the illness ( ). Group 2 was defined with days 5-7 ( ), group 3 with days 8-10 ( ), group 4 with days >10 ( ). A greater proportion of IVIG-resistant KD patients were group 4 than the other three groups, and there were significant differences ( ). The incidence of coronary artery lesions (CALs) and coronary artery aneurysms (CAAs) in group 3 and group 4 was higher than that in group 1 ( ) and group 2 ( ) during a 12-month follow-up. Additionally, the incidence of CALs in group 1 was higher than that in group 2 but without statistical significance ( ). The OR was significantly higher for those who started IVIG administration more than 7 days from the onset was positively associated with the occurrence of CALs (OR, 5.3; 95% CI, 2.0-13.9) and CAAs (OR, 13.5; 95% CI, 2.9-14.1) 12 months after initial onset. Multivariate regression revealed that the timing of IVIG treatment and IVIG-resistance was independent risk factors of CALs. Conclusions. IVIG treatment less than 7 days after illness onset are found to be sufficient for preventing developing coronary artery abnormalities in KD patients. Earlier IVIG treatment administration within 4 days may not increase the higher incidence of coronary artery abnormalities and IVIG resistance (Chinese Clinical Trial Registry:ChiCTR1800015800).

26 November 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XLXuemei Li
Xuemei Li
ZZZihan Zhou
Zihan Zhou
JFJingyi Fan
Jingyi Fan
LZLin Zhao
Lin Zhao
RXRuidi Xu
Ruidi Xu
CWCe Wang
Ce Wang
Background: Kawasaki disease (KD) is the primary cause of acquired heart disease in children. Intravenous immunoglobulin (IVIG) is the first-line therapy for KD; however, IVIG resistance can occur. Reliable treatment efficacy prediction tools for Chinese patients are lacking, which this study aimed to address. Methods: This retrospective cohort study enrolled patients diagnosed with KD admitted to Shengjing Hospital of China Medical University and collected data on 36 demographic, clinical, and laboratory parameters. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to identify key predictive variables. The dataset was divided into training (70%) and validation (30%) sets. Ten models were trained through 10-fold cross-validation, and the training set data were balanced using the ROSE method for oversampling. The performance of each model was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy. Patients with KD admitted to Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, between January 2023 and December 2024 were enrolled as an external validation cohort. Results: The CatBoost machine learning algorithm achieved the best comprehensive results (AUC: 0·960; sensitivity: 0·883; specificity: 0·889, and accuracy: 0·887). The internal validation results with CatBoost were AUC: 0·862; 95% confidence interval [CI]: 0·6453–0·7651; sensitivity: 0·716; specificity: 0·877; and accuracy: 0·861. The external validation results were AUC: 0·834; 95% CI: 0·783–0·884; sensitivity: 0·817; specificity: 0·838, and accuracy: 0·835. Conclusions: We present a machine learning model that can predict the risk of IVIG non-responsiveness in patients with KD in China. This model may help doctors develop personalized treatment strategies, thus improving the prognosis of KD.

3 August 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
WLWei Li
Wei Li
LZLi Zhang
Li Zhang
ZWZhouping Wang
Zhouping Wang
XHXiufang He
Xiufang He
HLHuimei Lin
Huimei Lin
PHPing Huang
Ping Huang
Background. Between 10 and 20% of Kawasaki disease (KD) patients are resistant to treatment with initial intravenous immunoglobulin (IVIG) and have a high risk of developing coronary artery lesions. Some studies have been conducted to identify predictive factors. However, the results are controversial. This study aims to identify the risk factors for IVIG‐resistant KD patients in a Chinese population. Methods. We performed a retrospective analysis of medical records of consecutive KD patients from two medical centers in South China from January 2015 to December 2017. A total of 1281 KD patients were eligible for inclusion in this study and maintained follow‐up for over 12 months. The KD patients were divided into two groups based on IVIG response. Clinical characteristics and laboratory variables were compared between the two groups. Multivariate logistic regression analysis was performed to identify the risk factors of IVIG resistance in KD patients. Results. Of the 1281 KD patients, 141 (11.0%) cases who were IVIG resistant to adjunctive therapies for primary treatment were classified as group 1. The remaining patients were in group 2 (n = 1140), classified as the control group. There was a significant difference in male to female ratio and the length of hospital stay between the two groups (P < 0.05). Group 1 had a higher white blood cell count (P = 0.01) and C‐reactive protein level (P < 0.01) before IVIG treatment than in group 2. Group 1 had a significantly higher white blood cell count and percentage of neutrophils after the IVIG infusion than in group 2 (P < 0.001). In addition, the mean values of C‐reactive protein level and neutrophil percentage before and after treatment difference comparison were significantly different. Multivariate analysis showed that patients presenting with coronary artery lesions in the acute phase and a C‐reactive protein level >100 mg/L at diagnosis were associated with IVIG resistance in KD. During the 12‐month follow‐up period, group 1 had an obviously higher incidence of coronary artery lesions than group 2, and the difference between the groups was statistically significant (P < 0.001). Conclusions. Patients presenting with coronary artery lesions in the acute phase and elevated C‐reactive protein levels before IVIG treatment might be a useful and important value for predicting IVIG resistance in KD. Risk assessment based on coronary artery lesions and C‐reactive protein levels prior to the treatment may improve the outcome of IVIG resistance.


23 February 2021 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
WLWei Li
Wei Li
LPLei Pi
Lei Pi
JYJia Yuan
Jia Yuan
XGXueping Gu
Xueping Gu
ZWZhouping Wang
Zhouping Wang
XGXiaoqiong Gu
Xiaoqiong Gu
Background. Kawasaki disease (KD) is a systemic vasculitis of unknown etiology in children. Coronary artery abnormalities are the most common complications of KD. Recent evidence showed that genetic polymorphisms may lead to susceptibility to KD. Genetic variants in platelet glycoprotein have been reported to be associated with coronary artery disease. The aim of the present study is to investigate the correlation between the role of platelet glycoprotein and coronary artery aneurysms in KD patients. Methods. We did a case-control study that enrolled 818 KD patients and 1401 healthy children with the same age and sex from January 2013 to December 2016. Analysis of single-nucleotide polymorphism (rs1126643) of the platelet glycoprotein Ia/IIa C807T was performed by multiplex polymerase chain reactions in this study. Results. A significant difference in the genotype distribution between KD cases and controls was observed for the glycoprotein Ia/IIa C807T (rs1126643) polymorphism ( ). Compared with the healthy children, the rs1126643T allele carriers had odds ratio (OR) of 0.63 for developing KD (TT vs. CC: adjusted OR = 0.62, 95% confidence interval (CI) = 0.43–0.88, ; TT vs. CT/CC: adjusted OR = 0.63, 95% CI = 0.44–0.889, ). Furthermore, we also found that children less than 60 months of age and female patients with rs1126643 T allele carriers had an adjusted OR of 0.66 (95% CI = 0.46–0.95) for noncoronary artery aneurysm patients ( ). Single-nucleotide polymorphism rs1126643 TT seems to represent a protective factor against KD in coronary artery aneurysm formation in multivariate analysis. Conclusions. The platelet glycoprotein Ia/IIa T allele carriers may have a protective effect on the risk of coronary artery aneurysms of KD patients, especially in females and children aged less than 60 months. These results may provide evidence for platelet glycoprotein Ia/IIa gene polymorphisms in the pathogenesis of KD patients.